Search Patents
  • NOVEL LISTERIA BACTERIOPHAGE TAILSPIKE PROTEIN AND USES THEREOF
    Publication number: 20140302495
    Abstract: The present invention relates to a novel tail spike protein (TSP) encoded by the novel Listeria bacteriophage designated ProCC P825 and uses of the novel TSP for identifying, detecting and monitoring of Listeria.
    Type: Application
    Filed: May 29, 2012
    Publication date: October 9, 2014
    Applicant: BIOMERIEUX SA
    Inventors: Holger Grallert, Sonja Molinaro, Julia Lorenz
  • RNA Replicon Encoding a Stabilized Corona Virus Spike Protein
    Publication number: 20210347828
    Abstract: RNA replicons encoding stabilized recombinant pre-fusion SARS CoV-2 S proteins are described. Also described are pharmaceutical compositions and uses of the RNA replicons.
    Type: Application
    Filed: May 11, 2021
    Publication date: November 11, 2021
    Inventors: Jason DEHART, Christian MAINE, Brett Steven MARRO, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Jaroslaw JURASZEK, Aneesh VIJAYAN
  • MONOCLONAL ANTIBODY FOR CORONAVIRUS SPIKE PROTEIN, AND USE THEREOF
    Publication number: 20230391854
    Abstract: Provided are an antibody or an antigen-binding fragment for a coronavirus S protein, a nucleic acid encoding the antibody or the antigen-binding fragment, a host cell comprising the nucleic acid, and a method for preparing the antibody or the antigen-binding fragment. Also provided is a use of the antibody or the antigen-binding fragment in prevention, treatment, and/or diagnosis of coronavirus.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 7, 2023
    Inventors: Jia ZOU, Li LI, Shuaixiang ZHOU, Jianxing HE
  • IMMUNOGENS DERIVED FROM SARS-COV2 SPIKE PROTEIN
    Publication number: 20230322867
    Abstract: The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.
    Type: Application
    Filed: July 22, 2021
    Publication date: October 12, 2023
    Applicant: AMGEN INC.
    Inventors: Fernando GARCES, Zhulun WANG, Timothy RILEY
  • HUMANIZED ACE2-FC FUSION PROTEIN FOR TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION
    Publication number: 20230235007
    Abstract: Disclosed herein are ACE2-Fc fusion polypeptides that contain at least one binding site for a spike protein of a coronavirus and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such fusion polypeptides.
    Type: Application
    Filed: June 15, 2021
    Publication date: July 27, 2023
    Inventors: Pan-Chyr YANG, Sui-Yuan CHANG, Kuo-Yen HUANG
  • Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins
    Publication number: 20230174591
    Abstract: Provided is a recombinant polypeptide comprising a resistin trimerization domain and a polypeptide of interest. Further provided is an expression vector encoding the recombinant polypeptide and a method of expressing the recombinant polypeptide. The polypeptide of interest may be a trimeric viral surface antigen or a portion thereof, such as the ectodomain of the SARS-CoV-2 spike protein. Further provided are compositions, such as immunogenic compositions and vaccines, comprising the recombinant polypeptide.
    Type: Application
    Filed: May 18, 2021
    Publication date: June 8, 2023
    Applicant: National Research Council of Canada
    Inventor: Yves DUROCHER
  • Spike tissue-specific promoter
    Patent number: 6291666
    Abstract: A spike tissue-specific promoter has been isolated, sequenced and tested. The promoter can be used to make gene constructs including a protein-coding sequence not natively associated with the promoter and a sufficient portion of the promoter such that the portion actuates the preferential expression of the protein-coding sequence in the spike tissue of cereal grain plants.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: September 18, 2001
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Sathish Puthigae, Ronald W. Skadsen
  • APTAMERS THAT SELECTIVELY BIND TO A SARS-COV-2 VIRUS NUCLEOCAPSID PROTEIN
    Publication number: 20240158799
    Abstract: The present invention is concerned with the detection of a SARS-Cov-2 vims antigen including, for example, a SARS-Cov-2 virus nucleocapsid protein and/or a SARS-Cov-2 virus spike protein. The present invention provides novel polynucleotide sequences which spontaneously fold to form aptamers having secondary structure features that promote selective binding to a SARS-CoV-2 virus antigen. The present invention further provides test kits and assay methods which employ the polynucleotides described herein, to achieve a more accurate, lower cost, rapid diagnosis COVID-19 test intended to accelerate contact tracing and testing of individuals and the community in the management of the ongoing global pandemic caused by various strains of SARS-CoV-2 virus.
    Type: Application
    Filed: February 24, 2022
    Publication date: May 16, 2024
    Inventors: Shalen Kumar, Angel Brito, Laura Trobiani, Saimon Moraes Silva
  • CORONAVIRUS VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO
    Publication number: 20230143228
    Abstract: This disclosure relates to methods of promoting immune responses against coronavirus, such as SARS-CoV-2, and compositions related thereto. In certain embodiments, this disclosure relates to methods of vaccinating for coronavirus comprising administering to the subject a composition disclosed herein. In certain embodiments, the composition comprises a recombinant virus such as recombinant MVA that encodes a coronavirus spike protein. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 986. In certain embodiments, the coronavirus spike protein comprises a proline mutation at position 987.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 11, 2023
    Inventors: Rama Rao AMARA, Sailaja GANGADHARA, Nanda Kishore ROUTHU
  • MONOCLONAL ANTIBODY AGAINST S PROTEIN OF MERS-CORONAVIRUS, AND USE OF SAME
    Publication number: 20210238261
    Abstract: The present invention relates to a monoclonal antibody specifically recognizing a spike protein of MERS coronavirus (MERS-CoV) or a part of the protein, or a functional fragment thereof, wherein the monoclonal antibody, or functional fragment of the monoclonal antibody characterized in that it comprises polypeptide sequence selected from the group consisting of the following polypeptide sequences: a heavy chain comprising a complementarity determining region 1(CDR 1) amino acid sequence consisting of the sequence of SEQ ID NO: 1, a CDR2 consisting of the sequence of SEQ ID NO: 2 and a CDR 3 consisting of the sequence of SEQ ID NO: 3; and a light chain comprising CDR1 amino acid sequence consisting of the sequence of SEQ ID NO: 4, a CDR2 consisting of the sequence of SEQ ID NO: 5 and a CDR 3 consisting of the sequence of SEQ ID NO: 6.and uses thereof.
    Type: Application
    Filed: August 13, 2019
    Publication date: August 5, 2021
    Inventors: Hyung Joo KWON, Byoung Kwon PARK, Dong Bum KIM
  • Corona-virus-like particles comprising functionally deleted genomes
    Publication number: 20050186575
    Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines therefor. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein which methods include decreasing the contact between heptad repeat regions of the coronavirus spike protein. The invention provides a peptide comprising a heptad repeat region of a coronaviral spike protein and/or a functional fragment and/or a derivative thereof. The invention also provides antibodies and compounds inhibiting coronaviral infection of cells, and/or cell-to-cell fusion. The invention also includes heptad repeat regions and a fusion peptide of SARS-CoV.
    Type: Application
    Filed: December 30, 2003
    Publication date: August 25, 2005
    Inventors: Petrus Rottier, Berend Bosch
  • VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOF
    Publication number: 20230084012
    Abstract: A novel transgene for use to produce a coronavirus vaccine is provided. The transgene encodes: i) an RNA polymerase promoter; ii) a 5? UTR; iii) a secretory sequence; iv) a coronavirus spike protein component, wherein the spike protein component incorporates a variant sequence at amino acid position 614 of a native spike protein; and v) a 3? UTR and poly A sequence. A vaccine is also provided comprising the transgene or an mRNA transcript thereof.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 16, 2023
    Inventors: Kakon Nag, Juwel Chandra Baray, Maksudur Rahman Khan, Asif Mahmud, Enamul Haq Sarker, Samir Kumar, Jikrul Islam, Rony Roy, Mohammad Mohiuddin, Naznin Sultana
  • NUCLEIC ACIDS, PROTEINS, AND VACCINES OF SARS-COV-2
    Publication number: 20230405109
    Abstract: Provided herein are, inter alia, SARS-CoV-2 spike (S) proteins; nucleic acids and plasmids encoding the proteins; vaccines and pharmaceutical compositions comprising the proteins, nucleic acids, or plasmids; methods for treating or preventing COVID-19; and methods for increasing immunity or providing acquired immunity to SARS-CoV in a subject.
    Type: Application
    Filed: November 11, 2021
    Publication date: December 21, 2023
    Inventors: Larry W. Kwak, Soungchul Cha, Szymon Szymura
  • A Diagnostic Device
    Publication number: 20230160894
    Abstract: A diagnostic device (1) for detecting a first member of a reporter-analyte pair. The diagnostic device comprises an inlet for receiving a liquid, biological sample and a porous membrane element (10) comprising a detection portion. The detection portion is in liquid communication with the inlet and a second member of the reporter-analyte pair is immobilised on the detection portion. One of the first or second member of the reporter-analyte pair comprises a biological antigen and the other of the first or second member of the reporter-analyte pair comprises an antibody specific for the biological antigen. The biological antigen comprises a spike protein, or a fragment thereof, of COVID-19. The device is for independent detection of the spike protein, or the fragment thereof, or of an antibody specific for the spike protein, or the fragment thereof, in the biological sample.
    Type: Application
    Filed: May 4, 2021
    Publication date: May 25, 2023
    Inventor: Simon Mico
  • GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN
    Publication number: 20160281109
    Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
  • GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN
    Publication number: 20090162320
    Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
    Type: Application
    Filed: October 27, 2006
    Publication date: June 25, 2009
    Applicant: DNAVEC Corporation
    Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa
  • GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN
    Publication number: 20150174198
    Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
    Type: Application
    Filed: November 17, 2014
    Publication date: June 25, 2015
    Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
  • GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN
    Publication number: 20190225986
    Abstract: The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
    Type: Application
    Filed: November 30, 2018
    Publication date: July 25, 2019
    Inventors: Katsuyuki Mitomo, Makoto Inoue, Hitoshi Iwasaki, Mamoru Hasegawa, Eric W. Alton, Uta Griesenbach
  • ORAL ADMINISTRATION OF CORONAVIRUS SPIKE PROTEIN FOR ALTERING CYTOKINE LEVELS AND PROVIDING PASSIVE IMMUNITY TO NEWBORN PIGS
    Publication number: 20220387581
    Abstract: Plants and plant produced compositions which include Coronavirus S proteins are disclosed. These may be used as vaccines, boosters or immune modulators. The compositions have been shown to reduce the inflammatory cytokine response by altering cytokine levels when administered to an animal. The compositions may be used as an immune modulator to reduce/ameliorate or prevent the cytokine storm often associated with Coronavirus or other virus infection. The compositions may also be used to produce additive protection when administered with any vaccine composition to increase vaccine effectiveness. The compositions when used as vaccines have been shown to protect newborn animals through passive immunity.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 8, 2022
    Inventors: John Howard, Gina Fake
  • SYNTHETIC PLASMID DNA VACCINE EXPRESSING A CODON-OPTIMIZED SARS-COV-2 SPIKE PROTEIN AND METHODS FOR ITS USE
    Publication number: 20220296700
    Abstract: A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 ?g of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 22, 2022
    Inventors: Anwar M. Hashem, Mohamed A. Alfaleh, Turki S. Abujamel, Sawsan S. Alamri, Abdullah Algaissi, Khalid A. Alluhaybi
Narrow Results

Filter by US Classification